Key result
Acetylcholine provocation tests were associated with a higher rate of serious cardiac complications or death than ergonovine tests (0.9% vs 0.4%; OR 1.75, 95% CI 1.13-2.69, P=0.011).
Why the study?
Does acetylcholine provocation testing increase the risk of serious cardiac complications compared to ergonovine testing in patients undergoing coronary angiography?
Cohort (n=21,512)
Yes
Does acetylcholine provocation testing increase the risk of serious cardiac complications compared to ergonovine testing in patients undergoing coronary angiography?
Odds Ratio: 1.75 (95% CI 1.13–2.69)
Absolute Event Rate: 0.9% vs 0.4%
p-value: p=0.011
In a large-scale Japanese cohort, acetylcholine provocation testing during coronary angiography was associated with a significantly higher risk of serious cardiac complications compared to ergonovine testing.
Warrants caution selecting acetylcholine over ergonovine for provocation testing; leaves open causality and need for randomized safety data.
BACKGROUND: Previous studies on complications with coronary spasm provocation tests were based on small sample sizes or were limited to high-volume centers. The risk of provocation tests using acetylcholine (ACH) or ergonovine (ER) remains to be fully examined by a large-scale multicenter study. HYPOTHESIS: ACH provocation tests are associated with a higher rate of serious cardiac complications than ER tests. METHODS: Using the Diagnosis Procedure Combination database in Japan, we identified patients aged ≥20 years who underwent a pharmacological provocation test during coronary angiography. We assessed the composite outcome of cardiac complications requiring urgent procedures (defibrillation, chest compression, intra-aortic balloon pumping, or extracorporeal membrane oxygenation) or death on the day of the provocation test, and compared the outcome between ACH and ER tests. RESULTS: Of 21 512 eligible patients in 602 hospitals, 10 628 (49.4%) underwent an ACH test and 10 884 (50.6%) underwent an ER test. The composite outcome occurred in 141 (0.7%) patients. The ACH group was significantly more likely to have the composite outcome than the ER group (0.9% vs 0.4%, P < 0.001). The propensity-score analyses showed consistent results (propensity score-matched, 0.9% vs 0.4%, P = 0.003; inverse probability-weighted, 0.8% vs 0.4%, P < 0.001). In a multivariable logistic regression analysis, ACH tests were significantly associated with a higher rate of the composite outcome than ER tests (odds ratio: 1.75, 95% confidence interval: 1.13-2.69, P = 0.011). CONCLUSIONS: This retrospective cohort study suggested that ACH tests were associated with a higher rate of cardiac complications than ER tests.
No takes yet. Share an insight, caveat, or question.
Isogai et al. (2015) conducted a cohort in Coronary spasm (n=21,512). Acetylcholine (ACH) provocation test vs. Ergonovine (ER) provocation test was evaluated on Composite outcome of cardiac complications requiring urgent procedures (defibrillation, chest compression, intra-aortic balloon pumping, or extracorporeal membrane oxygenation) or death on the day of the provocation test (OR 1.75, 95% CI 1.13-2.69, p=0.011). Acetylcholine provocation tests were associated with a higher rate of serious cardiac complications or death than ergonovine tests (0.9% vs 0.4%; OR 1.75, 95% CI 1.13-2.69, P=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: